GLPwatch

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.

BMC Pharmacol Toxicol · 2017

Last updated 2026-05-28

In a lab study on rat cells, two drugs—one a GLP-1 receptor agonist (exendin-4) and the other a PPARδ agonist (L-165,041)—reduced inflammation caused by high blood sugar by lowering levels of inflammatory markers IL-6 and TNF-α, decreasing RAGE protein, and preventing cell death. Both drugs worked at similar strengths, with 0.3 nanomolar exendin-4 and 1 micromolar L-165,041 showing comparable effects, and combining them further reduced inflammation but did not improve RAGE reduction or cell survival.

AI summary of the abstract below.

JournalBMC Pharmacol Toxicol, 2017
Citations34
Relative citation ratio1.42
NIH percentile63
Molecules
Conditions studied Type 2 Diabetes, Chronic Kidney Disease

Abstract

BACKGROUND: Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGE) production play major roles in progression of diabetic nephropathy. Anti-RAGE effect of peroxisome proliferator-activated receptor-delta (PPARδ) agonists was shown in previous studies. PPARδ agonists also stimulate glucagon-like peptide-1 (GLP-1) secretion from human intestinal cells. METHODS: In this study, the individual and synergic anti-inflammatory effects of GLP-1 receptor (exendin-4) and PPARδ (L-165,041) agonists in AGE-treated rat mesangial cells (RMC) were investigated. RESULTS: The results showed both exendin-4 and L-165,041 significantly attenuated AGE-induced IL-6 and TNF-α production, RAGE expression, and cell death in RMC. Similar anti-inflammatory potency was seen between 0.3 nM exendin-4 and 1 μM L-165,041. Synergic effect of exendin-4 and L-165,041 was shown in inhibiting cytokines production, but not in inhibiting RAGE expression or cell death. CONCLUSIONS: These results suggest that both GLP-1 receptor and PPARδ agonists have anti-inflammatory effect on AGE-treated rat mesangial cells.

Verbatim abstract via PubMed 29065926 ↗